[Polyvalent intravenous immunoglobulins in systemic lupus].
OBJECTIVE
To evaluate intravenous immunoglobulins (IVIG) treatment, which is immunomodulatory but not immunosuppressive, in SLE.


RESULTS
IVIG indications in SLE could be categorized as already validated as for chronic polyradiculoneuropathy or thrombocytopenia; failure of classical treatment in threatening active disease; undetermined manifestation as reactive hemophagocytic syndrome which could be both disease-specific or iatrogenic, infection-related. To date, no published study has firmly established the efficacy of IVIG in SLE.


CONCLUSIONS
IVIG therapy in SLE should be evaluated in prospective trials.
Papo
T
T
Service de médecine interne, Hôpital de la Pitié-Salpêtrière, Paris, France.
D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000276:immunology / Q000628:therapy*; D018579:Patient Selection; D011129:Polyradiculoneuropathy / Q000209:etiology; D013921:Thrombocytopenia / Q000209:etiology; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous